A detailed history of Ameriprise Financial Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 1,772,501 shares of BCRX stock, worth $13.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,772,501
Previous 1,865,623 4.99%
Holding current value
$13.4 Million
Previous $11.5 Million 16.84%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.41 - $8.69 $596,912 - $809,230
-93,122 Reduced 4.99%
1,772,501 $13.5 Million
Q2 2024

Aug 14, 2024

SELL
$4.13 - $6.79 $1.94 Million - $3.19 Million
-469,568 Reduced 20.11%
1,865,623 $11.5 Million
Q1 2024

May 15, 2024

BUY
$4.89 - $7.65 $5.49 Million - $8.58 Million
1,122,212 Added 92.52%
2,335,191 $11.9 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $2.8 Million - $3.81 Million
563,066 Added 86.64%
1,212,979 $7.27 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $46,137 - $54,457
6,876 Added 1.07%
649,913 $4.6 Million
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $2.15 Million - $2.72 Million
308,648 Added 92.3%
643,037 $4.53 Million
Q1 2023

May 15, 2023

SELL
$7.94 - $11.84 $3.95 Million - $5.9 Million
-497,936 Reduced 59.82%
334,389 $2.79 Million
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $3.29 Million - $4.45 Million
313,623 Added 60.46%
832,325 $9.56 Million
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $2.92 Million - $4 Million
270,419 Added 108.92%
518,702 $6.54 Million
Q2 2022

Aug 15, 2022

BUY
$7.89 - $17.88 $899,893 - $2.04 Million
114,055 Added 84.97%
248,283 $2.63 Million
Q1 2022

May 16, 2022

BUY
$11.56 - $19.76 $1.55 Million - $2.65 Million
134,228 New
134,228 $2.18 Million
Q3 2021

Nov 15, 2021

SELL
$14.21 - $17.65 $674,733 - $838,074
-47,483 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$9.5 - $17.24 $27,084 - $49,151
-2,851 Reduced 5.66%
47,483 $751,000
Q1 2021

May 17, 2021

SELL
$7.37 - $13.61 $149,168 - $275,466
-20,240 Reduced 28.68%
50,334 $512,000
Q4 2020

Feb 12, 2021

BUY
$3.37 - $8.61 $67,231 - $171,769
19,950 Added 39.41%
70,574 $525,000
Q3 2020

Nov 16, 2020

SELL
$3.43 - $5.53 $100,643 - $162,261
-29,342 Reduced 36.69%
50,624 $174,000
Q2 2020

Aug 14, 2020

BUY
$1.9 - $5.61 $151,935 - $448,609
79,966 New
79,966 $381,000
Q1 2020

May 15, 2020

SELL
$1.6 - $4.11 $174,430 - $448,068
-109,019 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.59 - $3.45 $34,612 - $75,103
21,769 Added 24.95%
109,019 $377,000
Q3 2019

Nov 14, 2019

BUY
$2.5 - $3.73 $218,125 - $325,442
87,250 New
87,250 $250,000
Q1 2019

May 15, 2019

SELL
$7.38 - $9.72 $872,485 - $1.15 Million
-118,223 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$6.51 - $9.6 $769,631 - $1.13 Million
118,223 New
118,223 $954,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.